> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Italfarmaco Awarded Priority Review Voucher
- URL: https://www.fdaweb.com/italfarmaco-awarded-priority-review-voucher/
- Published: 2024-04-10T12:00:00.000Z
- Updated: 2026-09-14T14:27:58.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5156749

*Federal Register* notice: FDA is announcing that it has issued a priority review voucher to Italfarmaco SpA for being the sponsor of a rare pediatric disease product application. FDA has determined that the company’s 3/21-approved Duvyzat (givinostat), indicated for treating Duchenne muscular dystrophy in patients six years of age or older, meets the criteria for a priority review voucher. To view the notice, click [here](https://public-inspection.federalregister.gov/2024-07657.pdf?ref=fdaweb.com).